Physician profile
Terry E Ham
NPI 1306891650
$7,221.82
in general payments reported to CMS, 2019-2025
48 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $854 · 2021: $862 · 2022: $854 · 2023: $1,319 · 2024: $1,279 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,997.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $796.84 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $675.37 | 2019-2025 | Veozah |
| Amgen INC. | $608.46 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $601.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $472.32 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $457.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $378.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.44 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $217.97 | 2021-2024 | |
| Dexcom, INC. | $172.22 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $150.55 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $126.98 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.79 | 2019-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $83.46 | 2022-2024 | Freestyle Libre |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.